In this retrospective analysis, we evaluated the combination of BV and RTx in patients with CD30-positive CTCL.<h4>Patients and methods</h4>We included 14 CD30-positive CTCL patients from six German cancer centers receiving BV; RTx was initiated within a timeframe of 3 months prior/after BV treatment. This evidence concerns the gene TNFRSF8 and cancer.